Unknown

Dataset Information

0

MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.


ABSTRACT: The lack of efficient tumor progression and chemoresistance indicators leads to high mortality in epithelial ovarian cancer (EOC) patients. Dysregulated miR-520g expression is involved in these processes in hepatic and colorectal cancers. In this study, we found that miR-520g expression gradually increased across normal, benign, borderline and EOC tissues. High miR-520g expression promoted tumor progression and chemoresistance to platinum-based chemotherapy, and reduced survival in EOC patients. miR-520g upregulation increased EOC cell proliferation, induced cell cycle transition and promoted cell invasion, while miR-520g downregulation inhibited tumor-related functions. In vivo, overexpression or downregulation of miR-520g respectively generated larger or smaller subcutaneous xenografts in nude mice. Death-associated protein kinase 2 (DAPK2) was a direct target of miR-520g. In 116 EOC tissue samples, miR-520g expression was significantly lower following DAPK2 overexpression. DAPK2 overexpression or miR-520g knockdown reduced EOC cell proliferation, invasion, wound healing and chemoresistance. This study suggests that miR-520g contributes to tumor progression and drug resistance by post-transcriptionally downregulating DAPK2, and that miR-520g may be a valuable therapeutic target in patients with EOC.

SUBMITTER: Zhang J 

PROVIDER: S-EPMC5041996 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.

Zhang Jing J   Liu Lei L   Sun Yunyan Y   Xiang Jiandong J   Zhou Dongmei D   Wang Li L   Xu Huali H   Yang Xiaoming X   Du Na N   Zhang Meng M   Yan Qin Q   Xi Xiaowei X  

Oncotarget 20160501 18


The lack of efficient tumor progression and chemoresistance indicators leads to high mortality in epithelial ovarian cancer (EOC) patients. Dysregulated miR-520g expression is involved in these processes in hepatic and colorectal cancers. In this study, we found that miR-520g expression gradually increased across normal, benign, borderline and EOC tissues. High miR-520g expression promoted tumor progression and chemoresistance to platinum-based chemotherapy, and reduced survival in EOC patients.  ...[more]

Similar Datasets

| S-EPMC4040687 | biostudies-literature
| S-EPMC10502110 | biostudies-literature
| S-EPMC4539686 | biostudies-literature
| S-EPMC11364787 | biostudies-literature
| S-EPMC10914313 | biostudies-literature
| S-EPMC5688927 | biostudies-literature
| S-EPMC6115398 | biostudies-literature
| S-EPMC8913663 | biostudies-literature
| S-EPMC6091081 | biostudies-literature
| S-EPMC8408112 | biostudies-literature